January 16, 2015
Toyama Chemical said on January 14 that it has begun a PII clinical study in Japan for the macrolide antibiotic solithromycin. According to the company, the compound exerts strong antibacterial activity against pneumococcus and mycoplasma strains resistant to existing macrolide...read more